

418 Rec'd PCT/PTO 03 MAY 1999

FORM PTO-1390
REV 5-93

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTORNEY'S DOCKET NUMBER

MAY 03 1999 418-015

U.S. APPLICATION NO. 09/297519

PARENT & TRADEMARK DATA

09/297519

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		PRIORITY DATE CLAIMED November 15, 1996
INTERNATIONAL APPLICATION NO. PCT/FR97/02022	INTERNATIONAL FILING DATE November 10, 1997	
TITLE OF INVENTION NOVEL POLYMERIC COMPLEXES FOR THE TRANSFECTION OF NUCLEIC ACIDS, WITH RESIDUES CAUSING THE DESTABILIZATION OF CELL MEMBRANES		
APPLICANT(S) FOR DO/EO/US MIDOUX et al		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A FIRST preliminary amendment.
- A SECOND or SUBSEQUENT preliminary amendment.
14. A substitute specification.
15. A change of power of attorney and/or address letter.
16. Other items or information: Verified Statement Claiming Small Entity Status (Small Business Concern); Drawings (9 sheets); PCT/IPEA/416; PCT/IPEA/409; PCT/IPEA/408;

17. The following fees are submitted:

Basic National Fee (37 CFR 1.492(a)(1)-(S)):

Search Report has been prepared by the EPO or JPO \$830.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) \$640.00

No international preliminary examination fee paid to USPTO (37 CFR 1.482)
but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$710.00Neither international preliminary examination fee (37 CFR 1.482) nor
international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$950.00International preliminary examination fee paid to USPTO (37 CFR 1.482)
and all claims satisfied provisions of PCT Article 33(2)-(4) \$90.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(c)).

Claims	Number Filed	Number Extra	Rate	
Total Claims	19 -20 -	0	X \$22.00	\$
Independent Claims	4 -3 -	1	X \$78.00	\$ 78.00
Multiple dependent claims(s) (if applicable)			+ \$230.00	\$
TOTAL OF ABOVE CALCULATIONS				= \$ 1048.00
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				= \$ 524.00
				SUBTOTAL = \$ 524.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+ \$
				TOTAL NATIONAL FEE = \$ 524.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ 40.00
				TOTAL FEES ENCLOSED = \$ 564.00
				Amount to be: refunded \$ charged \$

a. A check in the amount of \$ 564.00 to cover the above fees is enclosed.

b. Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2275. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:
Charles A. Muserlian
Bierman, Muserlian and Lucas
600 Third Avenue
New York, NY 10016

Charles A. Muserlian
SIGNATURE

Charles A. Muserlian

NAME
19,683

REGISTRATION NUMBER

**VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(c))--SMALL BUSINESS CONCERN**

Docket Number (Optional)
410.015

Applicant or Patentee: Patrick MIDOUX and Michel MONSIGNY

Serial or Patent No.: PCT/FR97/02022

Filed or Issued: November 10, 1997

Title: NOVEL POLYMERIC COMPLEXES FOR THE TRANSECTION OF NUCLEIC ACIDS,
WITH RESIDUES CAUSING THE DESTABILIZATION OF CELL MEMBRANES

I hereby declare that I am

the owner of the small business concern identified below;

an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN I.D.M. IMMUNO-DESIGNED MOLECULES

ADDRESS OF SMALL BUSINESS CONCERN 172, rue de Charonne, F-75011, Paris, France

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 37 CFR 1.112, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

the specification filed herewith with title as listed above;

the application identified above;

the patent identified above.

If the rights held by the above identified small business concern are not exclusive, each individual concern or organization having rights in the invention must file separate verified statements asserting to their status as small entities, and no rights in the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization having any rights in the invention is listed below:

no such person, concern, or organization exists.

each such person, concern or organization is listed below.

Separate verified statements are required from each named person, concern or organization having rights to the invention asserting to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Jean-Loup ROMET-LETONNE

TITLE OF PERSON IF OTHER THAN OWNER _____

ADDRESS OF PERSON SIGNING 172, rue de Charonne, F-75011, Paris, France

SIGNATURE Jean-Loup Romet-Letonne DATE April 14, 1999

09/297519

54 [REDACTED] 03 MAY 1999

410.015

"EXPRESS MAIL" Mailing Label Number EL323900938US

Date of Deposit: April 30, 1999

I hereby certify that this correspondence is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" Service under 37 CFR 1.10 on the date indicated above and is addressed to Asst. Commissioner for Patents, Washington, D.C. 20231.

Charles A. Muserlian

Charles A. Muserlian